Costs of treatment for age-related macular degeneration.
Gerson
Jeffrey D
JD
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy / Q000191:economics; D016527:Drug Costs; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics* / Q000503:physiopathology; D010778:Photochemotherapy / Q000191:economics*; D016896:Treatment Outcome; D014221:Triamcinolone / Q000191:economics / Q000627:therapeutic use; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D014221:Triamcinolone; D000068258:Bevacizumab